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Adjunctive raloxifene treatment improves attention and
memory in men and women with schizophrenia
TW Weickert1,2,3, D Weinberg2, R Lenroot1,2,3, SV Catts2,4, R Wells1,2, A Vercammen1,2,3,5, M O’Donnell1, C Galletly6,7, D Liu6,7, R Balzan6,8,
B Short2, D Pellen2, J Curtis1, VJ Carr1,3, J Kulkarni9, PR Schoﬁeld2,3,10 and CS Weickert1,2,3
There is increasing clinical and molecular evidence for the role of hormones and speciﬁcally estrogen and its receptor in
schizophrenia. A selective estrogen receptor modulator, raloxifene, stimulates estrogen-like activity in brain and can improve
cognition in older adults. The present study tested the extent to which adjunctive raloxifene treatment improved cognition and
reduced symptoms in young to middle-age men and women with schizophrenia. Ninety-eight patients with a diagnosis of
schizophrenia or schizoaffective disorder were recruited into a dual-site, thirteen-week, randomized, double-blind, placebo-
controlled, crossover trial of adjunctive raloxifene treatment in addition to their usual antipsychotic medications. Symptom severity
and cognition in the domains of working memory, attention/processing speed, language and verbal memory were assessed at
baseline, 6 and 13 weeks. Analyses of the initial 6-week phase of the study using a parallel groups design (with 39 patients receiving
placebo and 40 receiving raloxifene) revealed that participants receiving adjunctive raloxifene treatment showed signiﬁcant
improvement relative to placebo in memory and attention/processing speed. There was no reduction in symptom severity with
treatment compared with placebo. There were signiﬁcant carryover effects, suggesting some cognitive beneﬁts are sustained even
after raloxifene withdrawal. Analysis of the 13-week crossover data revealed signiﬁcant improvement with raloxifene only in
attention/processing speed. This is the ﬁrst study to show that daily, oral adjunctive raloxifene treatment at 120 mg per day has
beneﬁcial effects on attention/processing speed and memory for both men and women with schizophrenia. Thus, raloxifene may
be useful as an adjunctive treatment for cognitive deﬁcits associated with schizophrenia.
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INTRODUCTION
For the majority of those diagnosed with the illness, schizophrenia
is considered to be a debilitating mental disorder that often
responds inadequately to existing antipsychotic medications.1 One
of the characteristics of schizophrenia that is least responsive to
pharmacological treatment is cognitive impairment in the domains
of memory and attention,2 which are known to limit the vocational
prospects and quality of life for people with schizophrenia.3 Despite
decades of research into the cognitive deﬁcits of schizophrenia,
there are no satisfactory pharmacological agents capable of
restoring cognitive function. Thus, there is a great motivation to
develop adjunctive agents or additional therapies that can address
this unmet clinical need.4 Given that abnormalities of prefrontal
cortex and hippocampal function contribute to the cognitive
deﬁcits in schizophrenia, agents capable of restoring dysfunctional
neuronal processes in these regions may be used to develop novel
treatments for cognitive impairment associated with schizophrenia.
Sex hormones are known to have beneﬁcial effects in both cortex
and hippocampus.
Sex hormones may inﬂuence the course of schizophrenia, as the
onset of schizophrenia typically occurs in late adolescence.5 We
have shown that the adolescent sex hormones can change social
interactions, sensory motor gating and hippocampal neurogenesis
in nonhuman primates.6–8 Furthermore, the age of onset, course of
the illness, clinical presentation and response to treatment in
people with schizophrenia is different in women compared with
men.9–12 Women have a greater likelihood of developing
ﬁrst-episode psychosis or a symptom exacerbation when estrogen
levels are low, such as during an estrogen trough in the menstrual
cycle, post partum and around menopause.9,13–15 Conversely,
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schizophrenia symptoms can remit during pregnancy when
estrogen and progesterone levels are high.16 These observations
have led to the hypothesis that estrogen may have a protective role
against schizophrenia. In males, testosterone is converted to
estrogen in the brain. A previous study found that testosterone
was signiﬁcantly lower in men with schizophrenia than in healthy
males and that lower testosterone levels correlated with more
severe negative symptoms.17 We found that low normal testoster-
one levels in men with schizophrenia were related to poor cognitive
performance and altered cortical neural activity.18,19 Thus, both
estrogen and testosterone may modulate aspects of schizophrenia
in both men and women.
There is a substantial body of scientiﬁc literature supporting the
beneﬁcial effects of estrogen in the brain that includes preserva-
tion of memory and attention.20 In animal studies, restoration or
augmentation of endogenous estrogen promotes neuronal
growth, stimulates neuronal plasticity, increases synaptic spine
density and neurogenesis and improves neuroprotection against
excitotoxicity in cerebral cortex and hippocampus.21–23 We and
others have shown that estrogen receptors are localized to both
pyramidal and non-pyramidal neurons in the human prefrontal
cortex and hippocampus24,25 and we have identiﬁed many
different splice variants of the estrogen receptor alpha, which
potentially adds considerable diversity to how the human brain
may respond to circulating estrogen.26 Importantly, the estrogen
receptor is altered in the brains of people with schizophrenia,
involving both lower mRNA levels and/or failure to express the
fully functional wild-type form of the estrogen receptor.26,27 Our
molecular discoveries support and extend the estrogen hypoth-
esis by showing that the blunted ability of the brain to respond to
circulating estrogen may contribute to the pathophysiology of
schizophrenia in both men and women. These molecular changes
in the estrogen receptor suggest that the brain response to sex
hormones in men and women with schizophrenia may be
inadequate, a proposal that has been indirectly supported by
our in vitro cell culture experiments.27,28 Our molecular ﬁndings
coupled with the clinical observations noted above suggest that
cognitive function in men and women with schizophrenia may
beneﬁt from stimulation of the estrogen signaling pathway in the
brain. However, reversal of aging-related memory deﬁcits via
estrogen replacement strategies in healthy older females has
yielded mixed results.29
The inﬂuence of adjuvant estrogen on cognition in people with
schizophrenia is generally under explored. One small, preliminary
study reported signiﬁcant improvements in verbal memory with
estrogen replacement in postmenopausal women with
schizophrenia,30 whereas more recent studies with larger samples
demonstrated mixed results of hormone therapy on cognition in
premenopausal women with schizophrenia.31,32 Although studies
of the effects of estrogen on cognition in schizophrenia are
limited, several studies of estrogen therapy in schizophrenia have
demonstrated signiﬁcant symptom reduction in women with
schizophrenia and proof of principle studies suggest that addition
of estradiol may also be effective at accelerating symptom
reduction in men with schizophrenia.31,33–36 These studies are
encouraging regarding the potential value of estrogen as an
adjunctive treatment for both men and women with schizo-
phrenia. However, estrogen can carry some risks37 and there may
be undesirable adverse events of long-term adjuvant estrogen in
men. Thus, other treatments targeting the estrogen receptor that
can speciﬁcally stimulate estrogen action in brain cells and be
relatively free of adverse events in both men and women with
schizophrenia are needed. One such agent is the selective
estrogen receptor modulator raloxifene, which was shown to act
as an estrogen receptor agonist in the brain (and bone) and
antagonist in other tissues.38
Raloxifene, a second-generation selective estrogen receptor
modulator, is approved for use in the treatment of osteoporosis in
postmenopausal women and for breast cancer in women and can
have beneﬁcial effects on brain function including increased
cortical plasticity.39,40 Studies have reported that raloxifene at a
daily dose of 120mg preserved neural activity during a memory
challenge in healthy aging men41 and preserved cognition in
postmenopausal women.42 Recent clinical trials and case reports
have shown that adjunctive raloxifene at 60 or 120mg is
beneﬁcial for the treatment of positive, negative and general
psychopathology symptoms in postmenopausal women with
schizophrenia.43–45 One recent study also suggests that adjunctive
raloxifene administration at 60 mg per day improved memory and
verbal ﬂuency in a small cohort of postmenopausal women with
schizophrenia.46 However, to date, no clinical trials of raloxifene
have been reported in young adult to middle-age men and
women with schizophrenia. On the basis of our own ﬁndings that
the action of estrogen receptors in brain may be blunted in males
and females with schizophrenia and the previous studies showing
beneﬁcial effects of adjunctive raloxifene treatment on cognition
in older men and women, we predicted that adjunctive raloxifene
treatment at a daily dosage of 120mg would improve cognitive
deﬁcits, particularly in the domain of verbal memory, and reduce
symptoms in both men and women with schizophrenia.
MATERIALS AND METHODS
Participants
People with schizophrenia. From the 478 potential patients across
Australia (either responding to a national television program on
schizophrenia research or recruited from local clinics) who were screened
for participation in this study, 149 were excluded, 221 declined and 10
were lost to follow-up after completing the telephone screen, leaving a
total of 98 patients with schizophrenia or schizoaffective disorder being
recruited into two sites: either Neuroscience Research Australia, Randwick,
New South Wales, Australia (27 females and 49 males) or the Northern
Adelaide Local Health Network Mental Health Service, Adelaide, South
Australia, Australia (11 females and 11 males). All participants were
between 18 and 51 years of age and had been receiving antipsychotics for
at least 1 year before entering the study (see Supplementary Table 1 for
the frequency of people receiving each antipsychotic medication at entry
into the trial and the parallel group analysis). A diagnosis of schizophrenia
or schizoaffective disorder was determined using the Structured Clinical
Interview for Diagnostic and Statistical Manual IV-TR Axis I Disorders47 by a
clinician trained in administration of the SCID which was conﬁrmed
independently by another clinician. Patients with a concurrent Axis I
psychiatric diagnosis, a history of substance abuse or dependence (within
the past 5 years), head injuries with loss of consciousness, seizures, central
nervous system infection, untreated diabetes or hypertension, mental
retardation or contraindications to the administration of raloxifene were
excluded. Women were excluded if they were currently pregnant or were
receiving hormone therapy and refused alternate forms of birth control.
See Figure 1 for the CONSORT diagram.
Healthy comparison group. A group of healthy adults were also recruited
for a one-time assessment to provide a baseline comparison group.
Exclusion criteria consisted of a personal history of or a ﬁrst-degree relative
with a DSM-IV Axis I psychiatric diagnosis, history of substance abuse or
dependence (within the past 5 years), head injuries with loss of conscious-
ness, seizures, central nervous system infection, untreated diabetes or
hypertension or mental retardation. Eighty-seven healthy adults (41 females
and 46 males) between 20 and 50 years of age met criteria for entry into the
comparison group. Nineteen of the total healthy controls were recruited
from Adelaide and 68 were recruited from the Sydney area.
All participants provided informed written consent before entering the
study, which was conducted under protocols approved by the University of
New South Wales (07/121 and 09/187), South Eastern Sydney and Illawarra
Area Health Service (07-259) Human Research Ethics Committees and the
Queen Elizabeth Hospital Ethics and Human Research Committee, Adelaide
(2010188). The trial was registered with the Australian and New Zealand
Clinical Trials Registry, registration number: ACTRN12608000461392, with
the primary and secondary outcomes of cognitive (immediate and delayed
story recall, working memory and verbal ﬂuency) and symptoms measures
(positive and negative symptoms), respectively.
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Trial design
A 13-week, randomized, double-blind, crossover, placebo-controlled trial
was conducted in which patients alternated between receiving adjunctive
120mg per day of encapsulated raloxifene HCl orally and a placebo
(encapsulated lactose) in addition to their currently prescribed antipsy-
chotic medication. Encapsulation of raloxifene and placebo in addition to
all quality assessment/control testing (including cleaning validation and
International Conference on Harmonization stability trials) of the
compound over the duration of the study was performed by IDT Australia,
Victoria, Australia. Following the ﬁrst 6-week period of the trial, all patients
entered a 1-week ‘washout’ (raloxifene half-life = 27.7 h).48 After the
washout, all patients then entered the second 6-week period of the trial
consisting of the alternate treatment (raloxifene or placebo). Assessments
were made at baseline and at the end of weeks 6 and 13 by a psychologist
or psychometrician trained in administration and scoring. Patients were
monitored throughout the trial for the occurrence of adverse events. All
participants and study personnel were blind to the adjunctive treatment
status. The Prince of Wales Hospital Pharmacy Clinical Trials Unit used a
computer generated randomization schedule to assign patients to the
raloxifene-placebo or placebo-raloxifene treatment order conditions.
Treatment compliance and adverse events
At completion of the ﬁrst and second period of the study, participants
returned any remaining pills. Compliance was assessed based on the
percentage of tablets returned. All patients with treatment compliance
below 80% (total n= 9, period 1: 3 placebo, 1 raloxifene; period 2: 3
placebo, 2 raloxifene) were excluded from the analyses (see Figure 1). All
adverse events were recorded during the 13 weeks of the trial.
ASSESSMENTS
Cognitive assessments
At baseline only, all participants were administered a four subtest
version of the Wechsler Adult Intelligence Scale-Third Edition
(WAIS-III)49 (consisting of Arithmetic, Similarities, Picture Comple-
tion and Digit Symbol subtests) as an estimate of current IQ, and
the Wechsler Test of Adult Reading (WTAR)50 as an estimate of
premorbid intelligence. Additional cognitive assessments were
performed at baseline and at the end of 6 and 13 weeks of
treatment for all patients. Working memory, verbal ﬂuency,
attention/perceptual-motor processing speed and verbal memory
were assessed using the WAIS-III Letter-Number Sequencing (LNS),
the Controlled Oral Word Association Test (COWAT) letter
ﬂuency,51 Form A of the Trail Making Test (TMT-A)52 and Logical
Memory I and II (LMI and LMII) of the Wechsler Memory Scale
Revised,53 respectively. Identical versions of LNS and TMT-A and
alternate versions of the COWAT letter ﬂuency and LMI and II were
Figure 1. CONSORT ﬂow diagram.
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administered at each assessment. TMT-A was incorporated into
the battery after initiation of the trial, which resulted in a lower
total number of patients completing this measure.
Symptom, emotional and functional assessments
Symptom severity was assessed in patients at baseline and after 6
and 13 weeks of treatment using the Positive and Negative
Syndrome Scale (PANSS).54 Inter-rater reliability for the PANSS
scoring was high with an average intraclass correlation coefﬁcient
of 0.90. Negative emotional states, daily function and quality of life
were assessed with the 21-item version of the Depression Anxiety
and Stress Scale (DASS),55 the Short Form 36 Version 2 Health
Survey questionnaire (SF-36v2)56 and the Schizophrenia Quality of
Life Scale (SQLS),57 respectively.
Whole-blood assays
Fasting peripheral blood was taken between 0900 and 1100 hours
to control for alterations in hormone levels due to circadian
variations. Immediately following collection, clotted and hepar-
inized blood was delivered on ice to the pathology service at each
site. A hormone panel (consisting of follicle-stimulating hormone
and luteinizing hormone) and a coagulation panel, consisting of a
prothrombin time test, international normalized ratio and the
antithrombin III deﬁciency test, were assayed at baseline in patients
and controls and after 6 and 13 weeks of treatment in patients.
Blood measures were reviewed by two to three medical doctors for
changes in values that were outside the clinically normal range.
Statistical analyses
Data analysis was performed using IBM SPSS 22 for Windows.
Baseline demographics were compared between treatment order
conditions in patients using t-tests, Wilcoxon rank-sum tests or χ2-
tests as appropriate. Where possible, age- and sex-scaled scores
were used for the cognitive tests and all cognitive test scores were
standardized into z-scores relative to healthy participant means
and s.d.
Period effects, deﬁned as a change affecting an entire cohort
that is related to a particular period of time (that is, ﬁrst 6 weeks or
second 6 weeks), were assessed using paired t-tests comparing
period 1 with period 2 difference scores (week 6 minus baseline
versus week 13 minus week 6 for each outcome variable)
collapsing across treatment conditions. Potential carryover effects,
deﬁned as an effect that is retained or persists from one treatment
condition to the other, were determined for each outcome
measure using independent t-tests comparing the raloxifene/
placebo group to the placebo/raloxifene group on the sum of
their period 1 and period 2 difference scores.58
Owing to the evidence of carryover and period effects in our
preliminary analyses (see Results), we initially analyzed for primary
treatment outcomes using a parallel groups design from baseline
to the end of week 6 and then secondarily analyzed using the full
crossover design. To assess the treatment effects on cognition in
the ﬁrst 6-week phase only, a mixed multivariate analysis of
variance (MANOVA, with LNS, LMI, LMII, and COWAT as dependent
variables) were performed with time (baseline and after week 6) as
the within-subject factor and treatment condition (raloxifene
versus placebo) as the between-subjects factor. As TMT-A was not
available in the entire sample, the analysis of treatment effects on
TMT-A was performed separately using a mixed ANOVA with TMT-
A as the dependent variable. Symptom severity, emotional and
functional measures were each separately analyzed for treatment
effects using a series of mixed (M)ANOVAs (a mixed MANOVA for
PANSS positive, negative and general; a mixed MANOVA for DASS
depression, anxiety and stress; a mixed ANOVA for SF-36v2 total
and a mixed ANOVA for SQLS total). Post hoc Fisher least
signiﬁcant difference pairwise comparisons were used to identify
speciﬁc signiﬁcant effects after obtaining signiﬁcant overall (M)
ANOVA results and correction for multiple comparisons were
performed on the cognitive and symptom pairwise comparisons
separately using the Holm–Bonferroni method to control the
familywise error rate. Effect size calculations were measured as
Cohen’s d. Given that sex differences in raloxifene treatment was
not the main question we set out to address and our study was
not designed to assess sex related differences in raloxifene
treatment, we did not use sex as a grouping factor in the main
analyses; however, we did perform supplementary analyses using
sex as a grouping factor in the parallel group design.
To assess the overall crossover design results, difference scores
were calculated for each outcome measure for each phase (period
1: week 6 score minus baseline score, period 2: week 13 score
minus week 6 score). These difference scores were combined for
the raloxifene and placebo conditions, regardless of the period.
Treatment effects on cognition were analyzed using a repeated
measures MANOVA (with LNS, LMI, LMII and COWAT as dependent
variables) and a repeated measures ANOVA (with TMT-A as a
dependent variable) with treatment condition (raloxifene versus
placebo) as the within-subjects measure. Treatment effects for
symptom, emotional and functional measures were analyzed
using separate repeated measures MANOVAs (for PANSS and
DASS) and repeated measures ANOVAs (for SF36-v2 and SQLS)
with treatment condition (raloxifene versus placebo) as the within-
subjects factor.
Deﬁning responders
Responder analysis for the cognitive measures from baseline to
6 weeks was performed using the Jacobson–Truax Method of
deﬁning clinically reliable change with cutoff formula c.59 Reliable
change index measures used healthy control test–retest reliability
values from the WAIS-III and WMS-III technical manuals
(for LMI, LMII and LNS)49,53 and from Williams et al.60 (for COWAT
and TMT-A). Any patient who met the criteria of the Jacobson–
Truax method, which includes a signiﬁcant change from baseline
and meeting or exceeding a calculated threshold, on any of the
ﬁve cognitive outcome measures was considered a ‘cognitive
responder’. For symptom measures, response to treatment was
deﬁned as a 20% improvement on any symptom measure score as
suggested by Kane et al.61 Patients were grouped into two
categories, the ‘symptom responders’ with ≥20% symptom
severity reduction and ‘symptom non-responders’ who showed
o20% symptom severity reduction. χ2-tests were run to
determine whether the number of patients showing improve-
ments was signiﬁcantly different in either treatment condition and
Number Needed to Treat calculations were used to determine the
effectiveness of the intervention.
RESULTS
Demographics and baseline scores
Demographics and baseline scores for the treatment groups
based on assignment order (that is, raloxifene-placebo versus
placebo-raloxifene) are shown in Table 1. The treatment assign-
ment order groups differed signiﬁcantly at baseline on age of
disease onset and TMT-A scores. However, these differences were
relatively small, that is, less than 3 years of age and less than
20% difference in performance, respectively. There were no
other signiﬁcant differences between assignment order groups.
Thus, no signiﬁcant difference between the treatment order
groups in relation to PANSS-positive and -negative symptom
severity scores and other variables suggests that our study was
consistent with the recommendations provided in relation to
controlling for potential concurrent changes in symptoms and
cognition.62 See Supplementary Table 2 for the means and s.d. in
Raloxifene improves cognition in schizophrenia
TW Weickert et al
688
Molecular Psychiatry (2015), 685 – 694 © 2015 Macmillan Publishers Limited
relation to the demographic and cognitive variables in the healthy
participant group.
General outcomes of blood analyses, compliance and adverse
events
Blood analyses revealed statistically signiﬁcant main effects of
treatment, but no clinically relevant differences on the hormone
and coagulation panel measures between the raloxifene- and
placebo-treated groups (see Supplementary Table 3). Total
compliance for period 1 of the trial was 95.2% (n=79) and 88.8%
(n=71) for period 2. There were no signiﬁcant differences between
the frequencies of adverse events occurring at greater than or equal
to 3% in patients during raloxifene versus placebo treatment
phases (see Table 2). Throughout the course of the study, there
were no serious adverse events or suspected unexpected serious
adverse reactions that were attributed to the study medication.
There were two serious adverse events (a pneumothorax and a
seizure) that occurred during administration of raloxifene, which
resulted in discontinuation from the study for each participant;
however, in each case, the primary care treatment team determined
that these serious adverse events were unlikely to have resulted
from the administration of raloxifene.
Period and carryover effects
There were signiﬁcant period effects in the difference scores for
the cognitive, symptom and functional measures (see
Supplementary Table 4). Difference scores (improvement) in the
second 6 weeks (period 2 of the trial were signiﬁcantly less than
during the ﬁrst 6 weeks (period 1) for LMI, PANSS positive, general,
and total, and SF36-v2 total scores. Assessment of the carryover
effect amongst individual cognitive, symptom, emotional and
functional measures showed signiﬁcant carryover effects for LMI,
LMII and TMT-A (see Supplementary Table 5 and Supplementary
Figure 1).
Parallel groups design analysis of cognitive measures
Given that the carryover effects reported above may interfere with
attempts to detect treatment effects in the full crossover design
analysis, we performed a separate analysis of the treatment
outcomes at the end of the ﬁrst 6-week period in 40 patients
receiving raloxifene versus 39 patients receiving placebo using a
parallel groups design to determine the effects of raloxifene
without the potential confound of carryover or period effects. In
this analysis, patients receiving raloxifene showed signiﬁcant
Table 1. Baseline demographics cognitive, symptom and daily function measures for parallel groups analysis
Characteristics N Placebo ﬁrst N Raloxifene ﬁrst P-value
Age 39 34.0 (8.4) 40 37.4 (7.3) 0.06
Education 39 12.3 (2.2) 40 12.9 (2.8) 0.45
Age of disease
onset
39 22.1 (6.3) 40 24.1 (4.8) 0.02
Illness duration 39 12.2 (7.2) 40 13.4 (7.5) 0.51
Sex (number) 39 40 Χ2= 0.19
Male 27 22
Female 12 18





CPZ equivalents 39 530.4 (395.7) 40 529.0 (501.8) 0.98
Premorbid and current IQ
WAIS-III 39 90.8 (12.1) 40 91.7 (14.5) 0.78
WTAR 39 102.4 (8.8) 40 102.7 (8.9) 0.91
Cognitive tests
WAIS-III-LNS 39 7.8 (2.9) 40 8.4 (2.7) 0.40
WMSR-LMI 39 7.8 (3.6) 40 7.2 (3.2) 0.44
WMSR-LMII 39 6.1 (3.3) 40 5.9 (3.0) 0.76
TMT-A 28 35.3 (9.3) 29 41.8 (11.4) 0.02
COWAT 39 38.2 (10.6) 40 36.0 (11.2) 0.38
Symptom and daily function
PANSS
Positive 39 14.9 (4.3) 40 15.1 (5.3) 0.92
Negative 39 14.6 (7.0) 40 14.7 (5.7) 0.61
General 39 30.5 (8.1) 40 31.7 (9.7) 0.76
Total 39 60.0 (16.8) 40 61.4 (17.5) 0.72
DASS
Depression 39 11.6 (10.2) 40 12.2 (8.7) 0.56
Anxiety 39 10.7 (8.4) 40 9.2 (7.1) 0.49
Stress 39 14.7 (9.8) 40 13.6 (8.0) 0.61
SF-36v2 total 38 115.2 (16.5) 39 115.2 (19.5) 1.00
SQLS total 37 45.1 (16.7) 39 47.6 (16.8) 0.52
Abbreviations: COWAT, Controlled Oral Word Association Test; CPZ, chlorpromazine; DASS, Depression Anxiety and Stress Scale; IQ, intelligence quotient; LNS,
letter number sequencing; PANSS, positive and negative syndrome scale; SF-36v2, Short Form 36 Version 2 Health Survey Questionnaire; SQLS, Schizophrenia
Quality of Life Scale; TMT-A, trail making test A; WAIS-III, Wechsler Adult Intelligence Scale 3rd Edition; WMSR-LMI, Wechsler Memory Scale Revised Logical
Memory I; WMSR- LMII, Wechsler Memory Scale Revised Logical Memory II, WTAR, Wechsler Test of Adult Reading. Unless otherwise speciﬁed, values refer to
means and s.d. in parentheses.
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improvement on measures of cognition relative to the placebo
group. Results of the mixed (M)ANOVAs for the cognitive test
scores showed signiﬁcant treatment condition by time interac-
tions (combined cognitive tests treatment x time Wilks’ Lambda=
0.9, F(4,74) = 2.7, P= 0.04; TMT-A treatment x time Wilks’ Lamda =
0.9, F(1,55) = 6.0, P= 0.02), see Table 3. Follow-up, protected post
hoc least signiﬁcant difference tests with Holm–Bonferroni
corrections to control for familywise error rate in Table 3 show
signiﬁcant increases for raloxifene relative to placebo treatment in
relation to LMI (Po0.001), LMII (Po0.001) and TMT-A (Po0.001),
in which all survived correction for multiple comparisons. Medium
to large effect sizes were obtained for raloxifene treatment relative
to placebo, with effect sizes of 0.64 for LMI, 0.62 for LMII and 0.59
for TMT-A (see Table 3). Univariate results from the combined
cognitive measures MANOVA indicated a signiﬁcant interaction for
the COWAT measure, where the raloxifene treated group
improved and the placebo-treated group declined, but nonsigni-
ﬁcantly from their own baselines. Changes across all cognitive
measures are displayed for the ﬁrst 6 weeks of the trial in Figure 2.
See Supplementary Tables 6 and 7 for the results of our
supplemental analyses of the effects of raloxifene on cognition
that includes sex as a grouping factor and shows (in addition to
conﬁrming our main effects of raloxifene on memory and
cognition) a signiﬁcant interaction between sex and raloxifene
treatment on verbal ﬂuency in which females but not males show
improvement in verbal ﬂuency with raloxifene.
Parallel groups design analysis of symptom, emotional and
functional measures
Results of repeated measures (M)ANOVAs with treatment group as
the independent variable and symptom severity, emotional and
functional scores as dependent variables did not show any
signiﬁcant effects (see Table 3).
Responders analysis
Of the 40 patients administered raloxifene during the ﬁrst 6-week
period of the trial, 16 (40%) showed clinically reliable change on
one or more cognitive measures compared to only 6 out of 39
patients (15%) in the placebo condition. The cognitive measures
of Logical Memory I and II showed clinically reliable change with
the responders (see Supplementary Table 8). The χ2-test of
treatment response between the raloxifene and placebo groups
showed a signiﬁcant difference, χ2 (1) = 5.6, P= 0.02, with a
Number Needed to Treat of 4 needed to improve cognition with
raloxifene over 6 weeks.
χ2 comparison did not reveal any signiﬁcant differences in
relation to treatment conditions for patients with ≥20% symptom
score reduction versus o20% symptom score reduction
(see Supplementary Table 9). χ2-tests comparing responders and
non-responders on one or more symptom, emotional and
functional measures revealed no signiﬁcant differences between
raloxifene and placebo conditions and the odds ratio for response
Table 2. Adverse events during the 13-week raloxifene/placebo trial
Event Placebo (n= 90) Raloxifene (n=89) Fisher's exact P-value
Number Percentage Number Percentage
Symptom typea
Gastrointestinal disorders 8 9 17 19 0.06
Abdominal pain NOS 2 2 4 4
Constipation 3 3 4 4
Dyspepsia 0 0 3 3
Nausea 3 3 6 7
General disorders 4 4 3 3 1.00
Feeling abnormal 4 4 3 3
Metabolism and nutrition disorders 3 3 2 2 1.00
Abnormal weight gain 3 3 2 2
Musculoskeletal and connective tissue disorders 4 4 5 6 0.75
Cramps 4 4 5 6
Nervous system disorders 7 8 8 9 0.79
Headaches 3 3 3 3
Lethargy 4 4 5 6
Psychiatric disorders 20 22 24 27 0.49
Depressed mood 5 6 7 8
Sleep disturbance 0 0 3 3
Panic attack 2 2 3 3
Emotional distress 1 1 3 3
Psychotic behavior exacerbation 5 6 2 2
Paranoia exacerbation 4 4 3 3
Hallucinations exacerbation 3 3 3 3
Respiratory, thoracic and mediastinal disorders 3 3 4 4 0.72
Common cold 3 3 4 4
aSymptoms occurring in ⩾ 3% of patients; patients can be accounted for more than once, as they may experience multiple symptoms. Adverse events were
analyzed for the full crossover trial. Occurrences of adverse events were coded into low-level terms and system organ class using the Medical Dictionary for
Regulatory Activities (MedDRA). Fisher’s exact tests were used to compare the frequency of a given adverse event and system organ class occurrences (⩾3%)
between treatment conditions (raloxifene versus placebo) with period I and period II of the crossover trial combined. Blood measure variations over each
period were simpliﬁed into two categories: ‘abnormal change’ (a change deviating from the normal range) or ‘no abnormal change’ (no change or changes
within the normal range). Periods I and II were combined and the resulting frequencies were compared between raloxifene and placebo condition. Three
patients were withdrawn for acute adverse events that were later determined to be unrelated to treatment and seven individuals discontinued due to feelings
of adverse symptomatic changes (four were in the raloxifene condition at the time of discontinuation). There was no signiﬁcant difference in adverse events
that occurred in ⩾ 3% patients between the raloxifene and placebo condition.
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to raloxifene treatment on the symptom measures was 1.0
(conﬁdence interval = 0.3–2.2).
Crossover design analysis results
Treatment effects for the full 13-week crossover trial design
revealed a signiﬁcant treatment effect only on TMT-A, Wilk’s
Lambda 0.9, (1,47) = 4.3, P= 0.04, where the raloxifene condition
showed a signiﬁcant beneﬁt, mean difference (s.d.) =− 0.5, (1.0),
relative to placebo, mean difference (s.d.) =− 0.1, (0.7), see
Supplementary Table 10. The crossover design analysis did not
show any other signiﬁcant effects of raloxifene in relation to
cognitive, symptom, emotional or functional measures.
DISCUSSION
Our primary results based on the parallel group design analysis
demonstrates for the ﬁrst time that adjunctive treatment with
raloxifene at 120 mg daily in both men and women with
schizophrenia is associated with cognitive improvements in verbal
memory and attention/perceptual-motor processing speed. Rela-
tive to a placebo group, patients receiving raloxifene at 120mg
daily showed both statistically and clinically signiﬁcant changes in
cognition. These cognitive improvements support the hypothesis
that raloxifene can be used as a novel therapeutic agent to
ameliorate cognitive deﬁcits in both men and women with
schizophrenia.
There have been few drug treatment options to reverse cognitive
deﬁcits related to schizophrenia. Cognitive impairment in schizo-
phrenia is an important issue, as it can negatively inﬂuence the
ability to function socially and maintain employment.3,63 A recent
review of clinical trials conducted before April 2011 for cognitive-
Table 3. Cognitive and symptom outcomes in parallel groups analyses
Omnibus tests for measure x treatment x
visit interaction














Cognitive tests: condition × time 79 W-L 0.9 (4,74)= 2.7 0.04
WAIS-III-LNS 79 H-F 0.4 (1,78)= 1.9 0.17 − 0.2 (0.1) 0.03 0.23 − 0.0 (0.1) 0.80 0.03
WMSR-LMI 79 H-F 2.2 (1,78)= 4.2 0.04 − 0.3 (0.2) 0.07 0.26 − 0.8 (0.2) o0.001a 0.64
WMSR-LMII 79 H-F 1.4 (1,78)= 2.2 0.14 − 0.3 (0.2) 0.07 0.30 − 0.7 (0.2) o0.001a 0.62
COWAT 79 H-F 1.1 (1,78)= 4.6 0.03 0.2 (0.1) 0.08 0.21 − 0.1 (0.1) 0.21 0.14
TMT-A: condition × time 57 W-L 0.9 (1,55)= 6.0 0.02
TMT-A 0.1 (0.2) 0.77 0.05 0.7 (0.2) o0.001a 0.59
Symptom outcomes
PANSS tests: condition × time 79 W-L 1.0 (3,75)= 0.7 0.54
Positive − − − 1.2 (0.4) o0.01 0.27 0.8 (0.4) 0.05 0.16
Negative − − − − 0.0 (0.6) 0.96 0.00 0.9 (0.5) 0.11 0.17
General − − − 1.8 (0.7) 0.01 0.22 2.0 (0.7) o0.01 0.23
DASS tests: condition × time 78 W-L 1.0 (3,74)= 1.1 0.35
Depression − − − 1.1 (1.3) 0.39 0.11 2.9 (1.3) 0.03 0.34
Anxiety − − − 0.8 (1.1) 0.47 0.11 1.3 (1.1) 0.24 0.21
Stress − − − 2.2 (1.4) 0.11 0.24 0.9 (1.4) 0.52 0.11
SF-36v2 total: condition× time 77 W-L 1.0 (1,75)= 0.0 0.84 − 4.9 (2.1) 0.02 0.27 − 4.3 (2.1) 0.04 0.24
SQLS total: condition × time 75 W-L 1.0 (1,73)= 0.1 0.81 4.3 (2.2) 0.05 0.25 5.1 (2.1) 0.02 0.31
Abbreviations: COWAT, Controlled Oral Word Association Test; DASS, depression anxiety and stress scale; H-F, Huynh-Feldt value; LSD, least signiﬁcant
difference; PANSS, positive and negative syndrome scale; SF-36v2, short form 36 version 2 health survey questionnaire; SQLS, Schizophrenia Quality of Life
Scale; TMT-A, Trail Making Test A; W-L, Wilk's Lamda; WAIS-III-LNS, Wechsler Adult Intelligence scale 3rd Edition letter number sequencing; WMSR-LMI,
Wechsler Memory Scale Revised Logical Memory I; WMSR-LMII, Wechsler Memory Scale Revised Logical Memory II. aSigniﬁcant after Holm–Bonferroni
correction. Cohen's d calculated as (mean difference)/(s.d. pooled). Cognitive z-scores were used for cognitive analyses. Mean difference reﬂects the change
from baseline to 6 weeks for each condition, where a negative value is an improvement for LNS, LMI, LMII, COWAT and SF-36v2 and a positive value is an
improvement for TMT-A, PANSS positive, negative, general, DASS depression, anxiety, stress and SQLS total.
Figure 2. Treatment differences across cognitive measures in the
parallel groups analyses. *P≤ 0.05, **P≤ 0.001. Figure 2 shows
signiﬁcant improvement from baseline to 6 weeks on measures of
immediate verbal memory (Wechsler Memory Scale Revised Logical
Memory I, LMI), delayed verbal memory (Wechsler Memory Scale
Revised Logical Memory II, LMII), and attention/processing speed
(TMT-A Trail Making Test A) in the raloxifene treatment condition.
TMT-A results are inversed for comparability. Improvement on
memory, attention/processing speed, and verbal ﬂuency (COWAT
Controlled Oral Word Association Test) were signiﬁcantly greater in
the raloxifene treatment condition relative to the placebo treatment
condition (brackets). There was no signiﬁcant difference between
raloxifene and placebo conditions for Wechsler Adult Intelligence
Scale 3rd Edition Letter-Number Sequencing (LNS) test.
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enhancing drugs in schizophrenia showed meager ﬁndings.64 Of
118 trials analyzed, only 61 were completed and ﬁve had
interpretable outcomes with sufﬁcient effect sizes to support their
ﬁndings. Galantamine and minocycline have been the only
reported medications to show some cognitive efﬁcacy, although
both treatments displayed only small effect sizes in the range of
0.29–0.37.65,66 These novel treatments for cognitive deﬁcits in
schizophrenia do not act as traditional dopamine D2 receptor
antagonists. However, galantamine and minocycline are not widely
used as there are questions regarding efﬁcacy and safety. Thus, the
ﬁnding of a beneﬁcial effect of raloxifene on cognitive abilities in
both men and women with schizophrenia is of particular interest
since it is relatively safe for use, with few adverse events requiring
discontinuation as in our sample (see Table 2), when careful
screening is performed to minimize the risk of potential severe
adverse events. Other studies of postmenopausal women with
schizophrenia, non-psychotic premenopausal women and men
within the age range of participants in our study have also reported
that the use of raloxifene was relatively safe and generally well
tolerated.43,45,46,67,68 Although the potential for developing blood
clots is a serious concern with raloxifene treatment, the risk of blood
clot with raloxifene would appear to be comparable to the risk of
clot with the use of some forms of oral contraceptives, although the
risks in males have not been well established.
Estrogen has been associated with improved memory and
attention in multiple studies of non-psychotic men and women,
although there are exceptions.69,70 Our results are consistent with
ﬁndings of estrogen-promoted increases in synaptic spine density
in the hippocampus and prefrontal cortex, regions linked to
memory and attention.21,22 Therefore, our ﬁndings of cognitive
improvement on measures of logical memory, which has been
linked to hippocampal integrity, and form A of the trail making
test, which has been associated with prefrontal activation,71,72
have support from both basic neurobiology and from work in
other human conditions. The effects of raloxifene on memory and
attention are consistent with previous studies of hormone and
hormone modulators on cognition and in particular on verbal
memory. Our effect size of 0.64 for raloxifene treatment on verbal
memory in men and women with schizophrenia was comparable
to the effect sizes of 0.74 and 0.69 for long-term recall and
continuous long-term recall during a verbal memory test in older
men who displayed mild cognitive impairment and received
estradiol for 12 weeks.73
Although estrogen therapy has been similarly linked to better
performance on verbal ﬂuency tasks74 and raloxifene treatment in
particular has been related to better verbal ﬂuency in post-
menopausal females with schizophrenia,46 we did not ﬁnd a
signiﬁcant improvement in the raloxifene condition from baseline
to 6 weeks on verbal ﬂuency when examining men and women
combined. However, we did ﬁnd a signiﬁcant difference in the
direction of change in verbal ﬂuency between the raloxifene and
placebo group during period 1, with the raloxifene group
improving and the placebo group declining. Although placebo
group decline is not easily interpreted, it is possible that the
decrease in performance in the placebo group, despite a known
practice effect, was due to increased difﬁcultly on the alternate
COWAT form used at 6 weeks by comparison with the form used
at baseline.75 In addition, in our supplemental analysis using sex as
a grouping factor, we did show a signiﬁcant interaction between
sex and raloxifene treatment in which females showed a beneﬁt of
raloxifene on verbal ﬂuency, but here again the placebo female
group showed a decline in ﬂuency.
Despite the improvements in cognition, our study did not ﬁnd a
signiﬁcant difference between effects of raloxifene and placebo
on symptom, emotional or functional measures. Previous studies
of postmenopausal women with schizophrenia have shown
beneﬁcial effects of adjunctive raloxifene treatment on symptom
severity assessed by PANSS.43,45 Similarly, adjunctive estrogen
treatment studies have shown signiﬁcant symptom reduction
primarily in women with schizophrenia, although there was at
least one study showing that estrogen administration reduced
symptoms in men with schizophrenia.15,31,34–36 The results of our
present study do not support a generalized beneﬁcial effect of
raloxifene on symptoms in men and women with schizophrenia.
Our patient sample was mildly to moderately ill based on PANSS-
positive and -negative symptom scores and clearly had room for
symptom reduction. However, equal percentages of patients in
both raloxifene and placebo conditions showed symptom
improvement after 6 weeks of treatment.
There are a number of limitations to our study. One limitation
may have been the recruitment of patients displaying mild to
moderate symptom severity on the positive and negative
symptom assessment, although these patients did have room
for further symptom severity reduction. Recruitment of patients
without comorbidity would limit the generalizability of our results;
however, the aim was to determine the extent to which adjunctive
raloxifene improves cognition in schizophrenia and we also
wanted to be certain to limit the risk of adverse events. Having
a smaller sample size with treatment group baseline differences
for the Trail Making Test and period and carryover effects are also
potential limitations; however, in spite of all these factors that
could have generally worked against ﬁnding a signiﬁcant
difference between treatment conditions, we still obtained
signiﬁcant effects in both the parallel group and crossover design
analyses. Allowing administration of concomitant medications (for
example, benzodiazepines) that may interfere with cognitive
function would also be a potential limitation. However, the
number of patients receiving this class of medications were
relatively few and given that the number of participants receiving
this class of medication was larger in the raloxifene treatment ﬁrst
period, the ability to ﬁnd a signiﬁcant beneﬁcial effect of
treatment should have been diminished in our parallel groups
analysis, yet, strong, signiﬁcant beneﬁcial effects of treatment
were still demonstrated. Another limitation may pertain to a
concurrent change in symptoms and cognition; however,
although mean symptom severity improved (for positive and
general symptoms) in the raloxifene treated group, we found
there was also the same or a greater degree of mean
improvement in the placebo-treated group (as per Table 3). Thus,
there did not appear to be an undue inﬂuence of symptoms that
would be responsible for our observed beneﬁcial effect of
raloxifene on cognition. Use of a crossover design was a limitation.
Crossover trials are appropriate for studies of populations with a
chronic illness, where the treatment effects washout quickly, and
the outcome being measured may be quickly ‘reversible.’
Although schizophrenia is a chronic illness, raloxifene does have
a reasonably short half-life, and cognitive and symptom measures
were expected to return to near baseline with discontinuation of
treatment in schizophrenia; this seems not to have been the case.
Given that raloxifene modulates the hormonal estrogen receptor
and hormones may propagate long-term effects such as changing
gene expression, which promotes neuronal protection, synaptic
growth and reduces neuroinﬂammation;22,23 raloxifene may
produce longer-term “carryover” effects. In future studies,
raloxifene should be assessed in larger parallel group design
trials over a longer duration of treatment with continued
assessment after discontinuation of treatment. Treatment with
raloxifene for a longer duration would be expected to be relatively
safe given that the highest risk of deep vein thrombosis has been
reported to be during the initial months of treatment as per the
package insert.48 Also, studies of raloxifene in ﬁrst-episode
psychosis may be warranted as improving cognitive deﬁcits at
an early stage of the illness may improve overall prognosis.
In conclusion, our ﬁndings from a relatively large sample of men
and women with schizophrenia demonstrate for the ﬁrst time that
adjunctive administration of raloxifene at 120mg per day can
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improve cognitive outcomes particularly in the domains of verbal
memory and attention in both men and women with schizo-
phrenia. These ﬁndings also support the hypothesis of an
estrogen-related disease model of schizophrenia and provide a
potential novel treatment for cognitive deﬁcits in both men and
women with schizophrenia.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGMENTS
We thank Loretta Moore, Nick Vella, Merribel Kyaw, Selena Hu, Alice Rothwell, Richard
Morris and Beverly Hisee for screening participants, performing cognitive and
symptom assessments, data entry, management and monitoring. This work was
supported by the University of New South Wales School of Psychiatry, the National
Health and Medical Research Council (NHMRC) of Australia Project Grant no. 568807,
Neuroscience Research Australia, the Schizophrenia Research Institute utilizing
infrastructure funding from NSW Ministry of Health and the Macquarie Group
Foundation and the Australian Schizophrenia Research Bank, which is supported by
the NHMRC of Australia, the Pratt Foundation, Ramsay Health Care and the Viertel
Charitable Foundation. CSW is a recipient of the National Health and Medical
Research Council (Australia) Senior Research Fellowship (#1021970). JK has received
support for research from: AstraZeneca, Mayne Pharma, Servier, Eli Lilly, Janssen-
Cilag; honoraria as a speaker for Jansen-Cilag, Lundbeck, AstraZeneca and Bristol
Myers Squib and she is an advisory board member for Janssen-Cilag, Lundbeck,
Roche and Pﬁzer. The research described in this project was not supported by any
pharmaceutical company funding. CSW has been a paid consultant for Lundbeck and
Roche. PRS has received speaker fees from Janssen-Cilag.
REFERENCES
1 Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of
attaining and maintaining symptom remission by antipsychotic medication in the
treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res
2011; 133: 42–46.
2 Weickert TW, Goldberg TE. The course of cognitive impairment in patients with
schizophrenia. In: Sharma T, Harvey P (eds). Cognition in Schizophrenia: Impair-
ments, importance and treatment strategies. Oxford University Press: New York, NY,
2000; 3–15.
3 Green MF. What are the functional consequences of neurocognitive deﬁcits in
schizophrenia? Am J Psychiatry 1996; 153: 321–330.
4 Hyman SE. Revitalizing psychiatric therapeutics. Neuropsychopharmacology 2014;
39: 220–229.
5 Burke KC, Burke JD Jr, Regier DA, Rae DS. Age at onset of selected mental dis-
orders in ﬁve community populations. Arch Gen Psychiatry 1990; 47: 511–518.
6 Allen KM, Fung SJ, Rothmond DA, Noble PL, Weickert CS. Gonadectomy increases
neurogenesis in the male adolescent rhesus macaque hippocampus. Hippo-
campus 2014; 24: 225–238.
7 Morris RW, Fung SJ, Rothmond DA, Richards B, Ward S, Noble PL et al. The effect
of gonadectomy on prepulse inhibition and fear-potentiated startle in adolescent
rhesus macaques. Psychoneuroendocrinology 2010; 35: 896–905.
8 Richards AB, Morris RW, Ward S, Schmitz S, Rothmond DA, Noble PL et al.
Gonadectomy negatively impacts social behavior of adolescent male primates.
Horm Behav 2009; 56: 140–148.
9 Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003;
28: 17–54.
10 Gur RE, Petty RG, Turetsky BI, Gur RC. Schizophrenia throughout life: sex differ-
ences in severity and proﬁle of symptoms. Schizophr Res 1996; 21: 1–12.
11 Goldstein JM, Link BG. Gender and the expression of schizophrenia. J Psychiatr Res
1988; 22: 141–155.
12 Hafner H, Maurer K, Lofﬂer W, Riecher-R A. The inﬂuence of age and sex on the
onset and early course of schizophrenia. Br J Psychiatry 1993; 162: 80–86.
13 Gattaz WF, Vogel P, Riecher-Rossler A, Soddu G. Inﬂuence of the menstrual cycle
phase on the therapeutic response in schizophrenia. Biol Psychiatry 1994; 36:
137–139.
14 Hallonquist JD, Seeman MV, Lang M, Rector NA. Variation in symptom severity
over the menstrual cycle of schizophrenics. Biol Psychiatry 1993; 33: 207–209.
15 Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol
modulate schizophrenic symptomatology? Schizophr Bull 1994; 20: 203–214.
16 McNeil TF, Kaij L, Maimquist‐Larsson A. Women with nonorganic psychosis:
pregnancy's effect on mental health during pregnancy. Acta Psychiatr Scand 1984;
70: 140–148.
17 Akhondzadeh S, Rezaei F, Larijani B, Nejatisafa A-A, Kashani L, Abbasi SH. Corre-
lation between testosterone, gonadotropins and prolactin and severity of nega-
tive symptoms in male patients with chronic schizophrenia. Schizophr Res 2006;
84: 405–410.
18 Vercammen A, Skilleter AJ, Lenroot R, Catts SV, Weickert CS, Weickert TW. Tes-
tosterone is inversely related to brain activity during emotional inhibition in
schizophrenia. PLoS One 2013; 8: e77496.
19 Moore L, Kyaw M, Vercammen A, Lenroot R, Kulkarni J, Curtis J et al. Serum
testosterone levels are related to cognitive function in men with schizophrenia.
Psychoneuroendocrinology 2013; 38: 1717–1728.
20 Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev 2003; 24:
133–151.
21 Hao J, Rapp PR, Janssen WGM, Lou W, Lasley BL, Hof PR et al. Interactive effects of
age and estrogen on cognition and pyramidal neurons in monkey
prefrontal cortex. Proc Natl Acad Sci 2007; 104: 11465–11470.
22 Woolley CS, McEwen BS. Estradiol regulates hippocampal dendritic spine density
via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci 1994; 14:
7680–7687.
23 Wang J, Cheng CM, Zhou J, Smith A, Weickert CS, Perlman WR et al. Estradiol
alters transcription factor gene expression in primate prefrontal cortex. J Neurosci
Res 2004; 76: 306–314.
24 Perlman WR, Tomaskovic-Crook E, Montague DM, Webster MJ, Rubinow DR,
Kleinman JE et al. Alteration in estrogen receptor alpha mRNA levels in frontal
cortex and hippocampus of patients with major mental illness. Biol Psychiatry
2005; 58: 812–824.
25 Montague D, Weickert CS, Tomaskovic-Crook E, Rothmond DA, Kleinman JE,
Rubinow DR. Oestrogen receptor alpha localisation in the prefrontal cortex of
three mammalian species. J Neuroendocrinol 2008; 20: 893–903.
26 Perlman WR, Matsumoto M, Beltaifa S, Hyde TM, Saunders RC, Webster MJ et al.
Expression of estrogen receptor alpha exon-deleted mRNA variants in the human
and non-human primate frontal cortex. Neuroscience 2005; 134: 81–95.
27 Weickert CS, Miranda-Angulo AL, Wong J, Perlman WR, Ward SE, Radhakrishna V
et al. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk
for schizophrenia. Hum Mol Genet2008; 17: 2293–2309.
28 Wong J, Weickert CS. Transcriptional interaction of an estrogen receptor splice
variant and ErbB4 suggests convergence in gene susceptibility pathways in
schizophrenia. J Biol Chem 2009; 284: 18824–18832.
29 LeBlanc ES, Janowsky J, Chan BKS, Nelson HD. Hormone replacement
therapy and cognition: systematic review and meta-analysis. JAMA 2001; 285:
1489–1499.
30 Good KP, Kopala LC, Martzke JS, Fluker M, Seeman MV, Parish B et al. Hormone
replacement therapy in postmenopausal women with schizophrenia: preliminary
ﬁndings. Schizophr Res 1999.
31 Kulkarni J, Gavrilidis E, Wang W, Worsley R, Fitzgerald PB, Gurvich C et al. Estradiol
for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in
women of child-bearing age. Mol Psychiatry 2014.
32 Ko Y-H, Joe S-H, Cho W, Park J-H, Lee J-J, Jung I-K et al. Effect of hormone
replacement therapy on cognitive function in women with chronic schizophrenia.
Int J Psychiatry Clin Pract 2006; 10: 97–104.
33 Begemann MJH, Dekker CF, van Lunenburg M, Sommer IE. Estrogen augmenta-
tion in schizophrenia: a quantitative review of current evidence. Schizophr Res
2012; 141: 179–184.
34 Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial
of the effects of estrogen in acutely psychotic women. Schizophr Res 1996; 20:
247–252.
35 Kulkarni J, de Castella A, Headey B, Marston N, Sinclair K, Lee S et al. Estrogens and
men with schizophrenia: is there a case for adjunctive therapy? Schizophr Res
2011; 125: 278–283.
36 Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, Bailey M, Bartholomeusz C
et al. Estrogen in severe mental illness: a potential new treatment approach. Arch
Gen Psychiatry 2008; 65: 955–960.
37 Barrett-Connor E, Stuenkel CA. Hormone replacement therapy (HRT)—risks and
beneﬁts. Int J Epidemiol 2001; 30: 423–426.
38 Landry M, Lévesque D, Di Paolo T, Eacute R, Egrave S. Estrogenic properties of
raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat
forebrain. Neuroendocrinology 2002; 76: 214–222.
39 Khan MM, Wakade C, de Sevilla L, Brann DW. Selective estrogen receptor mod-
ulators (SERMs) enhance neurogenesis and spine density following focal cerebral
ischemia. J Steroid Biochem Mol Biol 2014; 146: 38–47.
40 González-Burgos I, Rivera-Cervantes MC, Velázquez-Zamora DA, Feria-Velasco A,
Garcia-Segura LM. Selective estrogen receptor modulators regulate dendritic
spine plasticity in the hippocampus of male rats. Neural Plast 2011; 2012: 309494.
Raloxifene improves cognition in schizophrenia
TW Weickert et al
693
© 2015 Macmillan Publishers Limited Molecular Psychiatry (2015), 685 – 694
41 Goekoop R, Duschek EJ, Knol DL, Barkhof F, Netelenbos C, Scheltens P et al.
Raloxifene exposure enhances brain activation during memory performance in
healthy elderly males; its possible relevance to behavior. NeuroImage 2005; 25:
63–75.
42 Nickelsen T, G Lufkin E, Lawrence Riggs B, A Cox D, H Crook T. Raloxifene
hydrochloride, a selective estrogen receptor modulator: safety assessment of
effects on cognitive function and mood in postmenopausal women. Psycho-
neuroendocrinology 1999; 24: 115–128.
43 Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M et al. Raloxifene as an
adjunctive treatment for postmenopausal women with schizophrenia: a double-
blind, randomized, placebo-controlled trial. J Clin Psychiatry 2011; 72: 1552.
44 Wong J, Seeman MV, Shapiro H. Case report: raloxifene in postmenopausal
women with psychosis: preliminary ﬁndings. Am J Geriatric Psychiatry 2003; 11:
697–698.
45 Kulkarni J, Gurvich C, Lee SJ, Gilbert H, Gavrilidis E, de Castella A et al. Piloting the
effective therapeutic dose of adjunctive selective estrogen receptor modulator
treatment in postmenopausal women with schizophrenia. Psychoneur-
oendocrinology 2010; 35: 1142–1147.
46 Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M et al. Effects of
raloxifene on cognition in postmenopausal women with schizophrenia: a double-
blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2014; 24:
223–231.
47 First MB. Structured clinical interview for DSM-IV-TR axis I disorders: SCID-I: bio-
metrics research department. New York State Psychiatric Institutute 2007.
48 Raloxifene: Highlights of Prescribing Information: Eli Lilly and Company. 2011.
Available at http://pi.lilly.com/us/evista-pi.pdf.
49 Wechsler D. Wechsler Adult Intelligence Scale. 3rd edn Pyschological Corporation:
San Antonio, TX, USA: 2001.
50 Wechsler D. Wechsler Test of Adult Reading. The Psychological Corporation: San
Antonio, TX, USA 2001.
51 Lezak M. Neuropsychological Assessment. 4th edn Oxford University Press: New
York, NY: 2004.
52 Reitan RWD. The Halstead-Reitan Neuropsychological Test Battery: Therapy and
Clinical Interpretation. Neuropsychological Press: Tucson, AZ, USA: 1985.
53 Wechsler D. Wechsler Memory Scale-Revised. The Psychological Corporation: San
Antonio, TX, USA, 1987.
54 Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale (PANSS)
for schizophrenia. Schizophr Bull 1987; 13: 261.
55 Lovibond S, Lovibond P. Manual for the Depression Anxiety Stress Scale. 2nd edn
Psychology Foundation: Sydney, Australia: 1995.
56 Ware JE, Kosinski M, Dewey JE, Gandek B. SF-36 health survey: manual and
interpretation guide: Quality Metric Inc. 2000.
57 Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V et al. Self-report
quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry
2000; 177: 42–46.
58 Woods JR, Williams JG, Tavel M. The two-period crossover design in medical
research. Ann Int Med 1989; 110: 560–566.
59 Jacobson NS, Truax P. Clinical signiﬁcance: a statistical approach to deﬁning
meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12.
60 Williams LM, Simms E, Clark CR, Paul RH, Rowe D, Gordon E. The test-retest
reliability of a standardized neurocognitive and neurophysiological test
battery:“neuromarker”. Int J Neurosci 2005; 115: 1605–1630.
61 Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant
schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen
Psychiatry 1988; 45: 789.
62 Buchanan RW, Davis M, Goff D, Green MF, Keefe RSE, Leon AC et al. A summary of
the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive
drugs for schizophrenia. Schizophr Bull 2005; 31: 5–19.
63 McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schi-
zophrenia. Schizophr Res 2000; 45: 175–184.
64 Keefe RSE, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M et al. Clinical
trials of potential cognitive-enhancing drugs in schizophrenia: what have we
learned so far? Schizophr Bull 2013; 39: 417–435.
65 Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G et al. A
double-blind, randomized study of minocycline for the treatment of negative and
cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138.
66 Buchanan R, Conley R, Dickinson D, Ball M, Feldman S, Gold J et al. Galantamine
for the treatment of cognitive impairments in people with schizophrenia. Am J
Psychiatry 2008; 165: 82–89.
67 Eng-Wong J, Reynolds JC, Venzon D, Liewehr D, Gantz S, Danforth D et al. Effect of
raloxifene on bone mineral density in premenopausal women at increased risk of
breast cancer. J Clin Endocrinol Metab 2006; 91: 3941–3946.
68 Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R. Raloxifene treatment is
associated with increased serum estradiol and decreased bone remodeling in
healthy middle‐aged men with low sex hormone levels. J Bone Miner Res 2004; 19:
1518–1524.
69 Boss L, Kang D-H, Marcus M, Bergstrom N. Endogenous sex hormones and cog-
nitive function in older adults a systematic review. West J Nurs Res 2014; 36:
388–426.
70 Salminen EK, Portin RI, Koskinen AI, Helenius HYM, Nurmi MJ. Estradiol and
cognition during androgen deprivation in men with prostate carcinoma. Cancer
2005; 103: 1381–1387.
71 Zakzanis KK, Mraz R, Graham SJ. An fMRI study of the Trail Making Test. Neu-
ropsychologia 2005; 43: 1878–1886.
72 Sass KJ, Sass A, Westerveld M, Lencz T, Novelly RA, Kim JH et al. Speciﬁcity in the
correlation of verbal memory and hippocampal neuron loss: dissociation of
memory, language, and verbal intellectual ability. J Clin Exp Neuropsychol 1992;
14: 662–672.
73 Sherwin BB, Chertkow H, Schipper H, Nasreddine Z. A randomized controlled trial
of estrogen treatment in men with mild cognitive impairment. Neurobiol Aging
2011; 32: 1808–1817.
74 Yonker JE, Adolfsson R, Eriksson E, Hellstrand M, Nilsson L-G, Herlitz A. Veriﬁed
hormone therapy improves episodic memory performance in healthy
postmenopausal women. Aging Neuropsychol Cogn 2006; 13: 291–307.
75 Barry D, Bates ME, Labouvie E. FAS and CFL forms of verbal ﬂuency differ in
difﬁculty: a meta-analytic study. Appl Neuropsychol 2008; 15: 97–106.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 International License. The images or
other third party material in this article are included in the article’s Creative Commons
license, unless indicatedotherwise in the credit line; if thematerial is not included under
the Creative Commons license, users will need to obtain permission from the license
holder to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)
Raloxifene improves cognition in schizophrenia
TW Weickert et al
694
Molecular Psychiatry (2015), 685 – 694 © 2015 Macmillan Publishers Limited
